Our entire business has been built to provide veterinarians and livestock producers the tools and information they need to “prevent the preventable” in order to keep their animals healthy and productive.

We utilize advanced techniques and technology coupled with our extensive experience in diagnostics to work with veterinarians to ensure proper sampling, easy submission, quick turnaround time and accurate results. Our diagnostic services are aimed at isolating and identifying viral and bacterial pathogens and providing the information you need to select proper antibiotic therapy as well as the ability to include virus and bacteria isolate in a custom (autogenous) vaccine to prevent future disease.

For over 40 years we have been focused on developing novel, effective bovine vaccines that provide immunity against existing and emerging diseases that affect stocker and feeder cattle.

When commercial vaccines are not providing you the protection you need against all of the viral and bacterial pathogens that are challenging your animals, we can manufacture a customized vaccine that fills the gaps your current vaccination protocol is leaving uncovered.

Bimeda Inc. is pleased to announce the formal renaming of acquired vaccine production, research and diagnostic company, Texas Vet Lab, Inc., as Bimeda Biologicals Inc. Both Texas Vet Lab, Inc. (TVL) and the VetBio, Inc. divisions of the business will henceforth operate under the new legal name of Bimeda Biologicals Inc.

Dave Cunningham, Bimeda's Chief Commercial Officer, commented, 'the renaming of the organization represents the first phase of our branding strategy and the continued integration of the TVL business, which is designed to see the company reach its potential both in domestic and export markets. The new name, Bimeda Biologicals Inc, respects the core identity of the business, while formally incorporating it into the Bimeda group of companies.'

Bimeda acquired the Texas-based biologicals business in December 2019, marking an important step for the company into the area of preventative medicines. At the time, Bimeda noted the company's significant potential for sustainable long-term growth and made a commitment to substantial investments to drive growth for both the existing vaccine portfolio and new product offerings.

For press queries, contact:
Dave Cunningham, Bimeda Chief Commercial Officer

Email: 

Bimeda^® is pleased to announce Rey Armendariz in the new role of Regional Strategic Manager. Effective immediately, Rey will be an integral part of the food animal sales team and assist in the sales development in feedlots for both core Bimeda products and the newly acquired bovine biologicals commercial and custom vaccine lines. Rey will assist the food animal business unit by also facilitating the business development and creation of strategies for key strategic feedlot accounts throughout a three-state territory (Kansas, Nebraska and Colorado).

Rey has 21 years of experience in multiple segments of the animal health industry working for Fort Dodge Animal Health and most recently with Zoetis in the confined feeding area.

Bimeda is very proud to add Rey to our growing food animal business unit.

Bimeda is pleased to announce the acquisition of Texas Vet Lab, Inc (TVL). Established in 1977 and located in San Angelo, Texas, TVL specialises in bovine vaccine research and production, with a broad range of live and inactivated vaccines to protect against cattle respiratory diseases.

Company CEO Gavin Tierney, commented; 'the acquisition of Texas Vet Lab marks an important step for Bimeda into the arena of preventative medicine. Following on from the integration of TVL, Bimeda is able to offer our customers a broad suite of both preventative and curative treatment options, including vaccines, antimicrobials, anti-parasitics, hormones, and anti-inflammatories.'

Tierney added, 'TVL also boasts an on-site laboratory, which provides diagnostics for antibiotic sensitivity, as well as virus and bacteria isolation and identification. This will allow us to provide customers with a diagnostics-led approach to the treatment of their animals; ensuring maximum efficacy and rapid recovery from disease.'

The US cattle vaccine market has demonstrated strong annual growth over the past five years and this trend is set to continue in line with the global movement towards preventative medicine, and a more targeted use of antibiotics. Against this backdrop, the acquisition will serve as an important tool for Bimeda's long-term growth strategy in the US.

Dave Cunningham, Bimeda's Chief Commercial Officer for North America, commented; 'Texas Vet Lab is an exciting acquisition for Bimeda. With decades of experience in developing innovative vaccines, the TVL team brings a commitment to quality, innovation and serving the customer which perfectly aligns with Bimeda's own values. We see significant long-term growth potential for the business, and with our substantial planned investments in R&D, Sales and Marketing, we will drive growth for both the existing vaccine portfolio and new product offerings.'

Director of Research & Development
Director of Research & Development, Bimeda Biologicals

National Account Manager - Cattle
USA

Senior Territory Manager
Colorado & West Kansas

Senior Territory Manager
Eastern New Mexico, Texas Panhandle, Oklahoma

Not All Adjuvants are Created Equal

Bimeda^® Biologicals Inc. was formed following Bimeda’s acquisition of Texas Vet Lab^®, Inc. (as well as their wholly owned subsidiaries VetBio^™, Inc. and Allied Biologics Company^™ Inc.) which have been in business since 1977. Our new name respects the core identity of the business, while formally incorporating it into the Bimeda group of companies.

Our state-of-the-art production facility, as well as our diagnostic and research labs, are located in San Angelo, Texas a city in the western part of the state that sits on the Concho River.

Staying true to the core competencies of Texas Vet Lab (TVL), we are a vaccine production, research and diagnostics company. We specialize in bovine biologicals and focus on the development of effective vaccines that provide immunity against existing and emerging diseases that affect stocker/feeder cattle.

In 2021 we have invested in both facilities and expertise to enter into the swine autogenous market segment by expanding our production facilities in San Angelo and opening a swine-focused state-of-the-art research and development lab in St. Paul, Minnesota. With our new R&D lab and expanded production facilities, our experienced swine team is able to provide veterinarians and producers support with strain selection, database management, whole genome sequencing (WGS), metagenomics, bioinformatics, clinical trials all in an effort to produce effective autogenous vaccines to improve their animals’ health and productivity.

Our talented team, which includes the legacy leadership and majority of TVL staff, strives to equip veterinarians and livestock producers with the tools and information they need to keep the animals in their care healthy and productive so that they can be profitable.

With the addition of the biological products and diagnostic services, Bimeda US is now able to provide livestock producers and veterinarians preventative solutions in addition to their existing portfolio which focused on five key categories including ecto- and endo-parasiticides, water soluble antimicrobials, injectables and nutritional products visit Bimeda USA to learn more.

To support veterinarians and livestock producers in their efforts toward keeping the animals they care for healthy and productive by providing them relevant, science-based solutions--through our vaccine production, research and diagnostic services—to effectively address the challenges they face.